<DOC>
	<DOC>NCT00047814</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.</brief_summary>
	<brief_title>Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>This is a multi-center, randomized, investigator and subject blinded, placebo-controlled eight week study, including a four week treatment period and a four week follow-up period. Three cohorts of HCV positive subjects will be studied in a sequential manner.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>The following criteria is a brief summary of Criterion required for trial participation. Inclusion Criteria Has chronic hepatitis C virus infection and has previously received at least three months of treatment with any approved therapy and failed to respond, relapsed or did not tolerate therapy Has positive HCV RNA by RTPCR Has abnormal ALT levels (at least 2 X ULN) Has liver biopsy within past 2 years consistent with chronic hepatitis, no evidence of nonalcoholic steatohepatitis or cirrhosis, and at least mild inflammation Has normal liver function indicated by: PT =&lt; 2 sec. prolonged compared to the ULN, Albumin &gt;= 3.5 g/dL, Total bilirubin =&lt; 1.5 mg/dL ANA titer =&lt; 1:160 Exclusion Criteria Has positive skin test for tuberculosis Has ALT value &gt;= 300 IU/L Has abnormal hematological parameters indicated by: ANC &lt; 1500/mm3 and Platelets &lt; 100,000/mm3 Has creatinine &gt; 1.5 X ULN AFP &gt; 50 ng/mL and evidence of hepatocellular carcinoma on ultrasound Is a carrier of the hepatitis B surface antigen (HBsAg), positive for HIV1 and/or HIV2 antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HCV</keyword>
</DOC>